Zealand Pharma may use acquisition option to beef up commercial muscle, CEO says

Should Zealand Pharma choose to exercise its options under its new financing agreement with Oberland Capital, opening up access to USD 200m, efforts to strenghten the firm's commercial business would likely be investigated, says CEO Emmanuel Dulac.
Emmanuel Dulac, CEO at Zealand Pharma | Photo: Stine Bidstrup/ERH
Emmanuel Dulac, CEO at Zealand Pharma | Photo: Stine Bidstrup/ERH
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

On Tuesday, Zealand Pharma secured a USD 50m option for potential acquisitions of products or companies in a financing agreement with private investment firm Oberland Capital.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading